Publications

• Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
• Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
• Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant

Specialties & Experience of this Expert Witness

Additional Information

I am a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. I am board certified in hematology as my practice focuses on malignant hematology, less commonly classical hematology. My outpatient practice focuses on myeloma and amyloidosis primarily with some lymphoma as well. My inpatient experience includes the lymphoma & myeloma service and the cell therapy service (autologous and allogeneic transplant, chimeric antigen receptor therapy). I am currently only involved as an expert witness for cases involving multiple myeloma, AL amyloidosis, plasmacytoma, smoldering myeloma, or monoclonal gammopathy. I am happy to work with plaintiff or defense lawyers to provide accurate opinions based on my clinical expertise in the field of plasma cell disorders. In order to provide timely reviews, I am not currently reviewing cases focused on 1) classical hematology (coagulation, blood clots, bleeding); or 2) solid tumor cases including (as examples) breast, colon, lung, or prostate cancers 3) carcinogenesis, i.e. pollutant exposure leading to the development of a blood or bone marrow cancer Once I catch up with my current cases, I will restart work on cases involving bleeding and clotting.